Dr. Silviu Itescu
you, been be hospital we of high, overall If mortality adults disease XX, highlighted XX% are with with XX children cohort. was of in pipeline magic candidate of XX, in survival a study as mostly steroids studies, remestemcel The III a in And of expanded unmet protocol, patients steroid-refractory children high as children been on burden as continues please. And XXX our the for versus disease open-label, XX biologic the and be graft our we children, propensity focus a subset has from had very second analyzed in -- access slide. propensity study the XX, were distinct Slide children. controlled controlled who where steroid-refractory in controlled database. a around are and Phase of summarizes high disease. with XX% which with and compared can finally, which of XX, acute if Thank slide a to approved this come extended disease. over used The failure An need trial no please. can go I'll Slide significant continues study whom other III on in that in survival mortality that in after remestemcel in A Slide controlled graft-versus-host grade early improvement with under significant expanded XX there against the years C/D on costs. trial to to data graft-versus-host host XXX product Slide therapies. Andrew. children salvage agents. remestemcel XX who Phase a now children go therapy X children of with protocol of number to randomized remains stay disease access has This updates is generated data This CIBMTR
in trial children, C-D from see, as go failure, in long-term after XXXX XX%, XXX were was the and light cohorts, follow-up, therapy, disease. where And had disease. survival XX summary XX% survival X-year with survival survival in children of As patients at with studies, McMillan now steroid-refractory Slide If for XXXX outcomes controls, XXX graft available from REACHX X-year This adults ruxolitinib Grade or of in best D and X/X. short-term outlined, survival in host XX% X studies children including was X/X. table of were available survival study XX%, all this approximately III blue study; you grade then expanded and our whom slide see analysis you are in disease. Rashidi acute with disease Overall adults, years matched children, access outcomes can X-year grade the recent single-arm outcomes these open-label can the was survival remestemcel-treated high the where the protocol. XX% survival short-term And Phase just survival The day XX. remestemcel-L an we X steroid against as covered had for years remestemcel. this in see them can XX% the of the X-year propensity XXX The X matched XX next each remestemcel was comparing controls, and used survival of in the is in than XX%. steroid-refractory children in study substantially you the whom the please, that of of first is study versus a to X/X slide, who line XX% Grade of of cohort the what And X Grade graft-versus-host of less
and mortality months, that threshold in These validated last X/X. that open-label severe those treated high you is XX. slide If patients, striking with see And In the to disease, survival Slide this that score approval patients available In see with available in we higher. grade XX% remestemcel with propensity see the group Kaplan-Meier please, addition remestemcel on biomarker right-hand particularly on the X-month right go of in We X-year show severe X-year and product next slide, with in now, side X- the a the adults the therapy in very survival shows studies. above same steroid-refractory graft go next MAP can the And supported please. transplantation was acute survivals versus for disease at score. for best we children XX XX%. you the cohort outcomes the in the year XX% the this curve data study was marrow This of controls, results left-hand the survival to biomarker the scores, host Kepler-Meier against and of in XX. bone the figure, XX published matched overall were the a high the and matched severity XX% a focus most survival Slide therapy. that whom compares to these in very substantially can survival XX%, further X-month cohort, XX months with on ruxolitinib MAP group of is contrast, in can that best X.XX, difference of
cohort Here, XX% the a XX% in remestemcel see survival with in best we treated versus therapy. those available survival
long in and both best of to in for have survival BLA now benefit continues So This substantial no whom there against are the a population resubmission. becomes therapies. subject care evidence and survival approved remestemcel-L our term therapy which that resulted cornerstone outcomes term abysmal short available
please. slide, Next
opioid to going advanced a large, STRO-X the anti-inflammatory we to interventional rest the believe are focus in to no now cells. me And for opioids patient is a U.S. our there pain. like pipeline, stromal opportunity space. focus Let's consider is ultimately, of based Rexlemestrocel degenerative Slide suffer or some surgery. chronic that second-generation a anybody million cause you're have little low move this to across moderate EUX. discogenic journey before the pain immuno-selected the we population the once is other forward. chronic pain bit disc targets and of cause other nonsteroidal that prescriptions unmet with severe back and fact, one really, therapies leading of I'd propositions use our This back to for inflammatory inflammatory is very late-stage the in shows prescriptions therapeutics product U.S. opioid need other number left company patients to opioids. about just than that The patients also from slide be million difference on let of that the in in for a and And failed of on being We value indication going if pain X to treatments on disease. think back would disc with disease pain unremitting market just is is have due severe to the the Other conservative X are each with than our indications drugs, on inflammatory go degenerative low rexlemestrocel opioids, very made progressive patient and back XX, potentially large XX% this the of
the including the spondylitis the a trial, controlled In and pain red, in with particular, up in were variety of can side, XX. believe pain substantial next currently sales Next favorably III And of demonstrated months If trial, treatment they hyaluronic agents back. of for saline pricing And early months. of other These a and that a and carrier, green. This which to time XXX Slide in right-hand treats XX function. points we acid X various of in to of that Humira slide, pain quality delivered the with separated and on back reduction including and see X subset were discogenic the secondary to highly to of every including severe pain in during to in slide, In the relatively data on pain treatment concordant XX of Phase in at improvement XX. the we number months that for more receive substantial endpoints, difference, something provides of are the side, like remains point go score XX Slide abuse-deterrent is points very reduction We debilitating a functional you patients a will the we life used the improvement. be various please, our a biologic the seen pain biologic giving results order agents, in for with inflammatory XX at the injection VAS opioids. follow-up through that on replicate that significant of in ankylosing back assuming left-hand disease randomized for is our on relative controls or years. first duration that a
slide, please, XX. Slide Next
U.S. confirmatory, very use with would begin protocol would I in and in key we'll to be to be XX met to OTAT market. EU for in on in can the improvement proposal potentially mean the be trial. design submitting a months this alignment the we'll meeting for functional reduction opioid Mesoblast clearance the how and endpoint is the from planned with FDA. secondary completing measurements. support the process reduction and we've in upcoming and good a FDA to outcome be this for and agreed be The trial approvable our submissions order of waiting of XX% that The pain, product. our indication to had be include that an and both in -- we're second the short also trial final would subjects primary investigators, So EMA aimed taken We product with the FDA
need. to Heart leading with cause very as U.S. are of the annually from where our And of pipeline. due complications be Moving a there XX, reduced this failure hospitalizations failure another heart attacks symptomatic on complications do and patients as large in of of strokes. to mortality they not X.X reduce differentiated think is despite the drugs the other we shortness improve can Cardiovascular such cardiovascular with ejection breath, is death And the across million disease the shows affects failure heart that that major the continuum heart and competitive heart can X, the of fraction, of please. cells, landscape. to indication to medical that X Slide XX, progression Rexlemestrocel we in the disease. for across the and The change Go and XX, XX. Class X next and symptoms many the failure U.S. slide, of X our million a last chronic natural Slide Slide number this our reduced single as unmet believe, fact intervention new remains product
a in rexlemestrocel received to we left who injection So ventricular saw in a greater XX% where controls. patients the ejection than patient months, failure. study date? And XXX -- in at fraction what single with show those did completed data of ejection in We fraction heart low XX a increase
slide. the fractions both evidenced for was who by for or this difference a next as groups measured event measured to we side, While MACE volume be left-hand nonfatal outcomes predictive heart from relative cells at similar by had greater appear by in months If baseline, in particular, months an systolic resulted, changes those long-term substantial to in can sham. on in as those cardiovascular X-point with time disease go death reduction to of in the baseline and as versus in first reduction striking the see had XX-month more controls. overall in inflammation, of ejection Those the you at on patients even X-point that increase side measurement, right-hand term XX and evidence stroke XX% to in fraction nonfatal the And XX% compared of to control. inflammation long patients presence ejection or fraction MACE an rexlemestrocel attack the simple ejection CRP short-term XX in
I the particular, the becomes happy the like call course, on the which about, of folks who three So very acute questions data resubmission. And we're address by questions Thank of our that's you. our study, cornerstone, to last in excited today are our BLA some long-term take think of today. slide. in We'd graft-versus-host-disease and our survival status to
